Bapineuzumab Trial Failure May Signal Bleak Outlook for New Alzheimer’s Drugs

Drug Industry Daily
A A
Pfizer, Johnson & Johnson (J&J) and Elan’s termination of their late-stage program for investigational Alzheimer’s drug bapineuzumab following the second failed study may not negatively impact the companies but could foreshadow a bleak outlook for the future of Alzheimer’s drug development, analysts say.

To View This Article:

Login

Subscribe To Drug Industry Daily